Choosing the first biologic in pediatric Crohn's disease: Evidence, uncertainty, and the continuing role of anti-TNF therapy
Best Practice & Research Clinical Gastroenterology · 2026-10 · 102163
DOI: 10.1016/j.bpg.2026.102163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Best Practice & Research Clinical Gastroenterology, 2026-10. Verfasst von Toshihiko Kakiuchi. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Kakiuchi, T. (2026). Choosing the first biologic in pediatric Crohn's disease: Evidence, uncertainty, and the continuing role of anti-TNF therapy. Best Practice & Research Clinical Gastroenterology, 102163. https://doi.org/10.1016/j.bpg.2026.102163
Vancouver
Kakiuchi T. Choosing the first biologic in pediatric Crohn's disease: Evidence, uncertainty, and the continuing role of anti-TNF therapy. Best Practice & Research Clinical Gastroenterology. 2026:102163. doi:10.1016/j.bpg.2026.102163
BibTeX
@article{Kakiuchi2026,
author = {Kakiuchi, Toshihiko},
title = {Choosing the first biologic in pediatric Crohn's disease: Evidence, uncertainty, and the continuing role of anti-TNF therapy},
journal = {Best Practice & Research Clinical Gastroenterology},
year = {2026},
pages = {102163},
doi = {10.1016/j.bpg.2026.102163}
}
EUVIMED